A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (CONNECT2)

Study Title
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma
Teva Identifier
FSS-AS-40139
ClinicalTrials.gov Identifier
NCT04677959
Study Status
Completed
Trial Condition(s)
Asthma
Interventions
Drug: Fluticasone propionate/salmeterol (FS) | Drug: Albuterol | Drug: Standard of Care Asthma Medication | Drug: Standard of Care Rescue Medication
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
respiratory-icon

Key Participation Requirements

Gender
Female, Male
Age group
Child, Adult, Older Adult
Age Range
13 Years and older
Trial Duration
February 16, 2021 - March 10, 2022
Phase
Phase 4

Study Type

Interventional